The markets took another nose-dive today and thankfully we have positioned ourselves with very little capital tied into the markets. The portfolio has plenty of cash on the sidelines, ready to strike when the time is right.
The markets have been volatile, and we are handling this like pros!
Keep it up.
Just a reminder, charts and targets are updated every Monday morning!
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.
Catalyst Swing names (1 – 4 week holds) I am watching…
Insys Therapeutics (INSY)
Catalyst Dates: May 22 Advisory Committee Meeting
Buy Zone: $5.65 to $6.15
Profit Zone: $7.00 or higher
Stop Zone: $5.45 or below
Galectin Therapeutics (GALT)
Catalyst Dates: Late breaking data due out April 14
Buy Zone: $4.25 to $4.50
Profit Zone: $5.20 or higher
Stop Zone: $4.00 or below
Esperion Therapeutics (ESPR)
Catalyst Dates: Two Phase 3 data sets due out in May
Buy Zone: $70.00 to $72.00
Profit Zone: $77.00 or higher
Stop Zone: $69.00 or below
Cymabay Therapeutics (CBAY)
Catalyst Dates: Data due out at the EASL conference April 11-15
Buy Zone: $12.25 to $12.50
Profit Zone: $13.50 or higher
Stop Zone: $12.00 or below
Karyopharm Therapeutics (KPTI)
Catalyst Dates: Phase 2b data due out at the end of April
Buy Zone: $13.00 to $13.75
Profit Zone: $15.00 or higher
Stop Zone: $12.75 or below
Corium International (CORI)
Catalyst Dates: Phase 1 data due likely in May
Buy Zone: $11.25 to $11.75
Profit Zone: $13.00 or higher
Stop Zone: $10.50 or below
AcelRx (ACRX)
Catalyst Dates: European approval likely due within next two months
Buy Zone: $2.00 to $2.20
Profit Zone: $2.50 or higher
Stop Zone: $1.80 or below
Exelixis (EXEL)
Catalyst Dates: Phase 3 cancer data due in the first half of 2018
Buy Zone: $21.00 to $23.00
Profit Zone: $27.00 or higher
Stop Zone: $20.50 or below
Achaogen (AKAO)
Catalyst Dates: Advisory Committee meeting on May 2nd. FDA approval dateJune 25th.
Buy Zone: $12.00 to $13.00
Profit Zone: $14.00 or higher
Stop Zone: $10.75 or below
AVEO Pharmaceuticals (AVEO)
Catalyst Dates: Phase 3 data due out in the second quarter
Buy Zone: $2.80 to $3.00
Profit Zone: $3.50 or higher
Stop Zone: $2.60 or below
Pluristem (PSTI)
Catalyst Dates: Phase 2 data due out in the second quarter
Buy Zone: $1.35 to $1.45
Profit Zone: $1.75 or higher
Stop Zone: $1.20 or below
Kitov Pharma (KTOV)
Catalyst Dates: FDA Approval date of May 31
Buy Zone: $2.10 to $2.30
Profit Zone: $2.75 or higher
Stop Zone: $2.00 or below
TherapeuticsMD (TXMD)
Catalyst Dates: FDA approval date of May 29th
Buy Zone: $4.60 to $5.20
Profit Zone: $6.00 or higher
Stop Zone: $4.50 or below
Medicinova (MNOV)
Catalyst Dates: Phase 1b/2a abstract to be presented April 27th
Buy Zone: $9.50 to $10.50
Profit Zone: $12.00 or higher
Stop Zone: $9.00 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $25.00 to $27.00
Profit Zone: $30.00 or higher
Stop Zone: $24.00 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.00 to $5.40
Profit Zone: $7.00 or higher
Stop Zone: $4.90 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.